Akeso / 康方生物

Akeso / 康方生物 is the Chinese biotech company used in vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位 as the episode’s clearest example of a Chinese clinical asset changing global pharma behavior. The source focuses on its PD-1/VEGF bispecific readout and the way 默沙东 publicly asked for longer survival evidence while later moving to buy a related Chinese asset.

The page is source-scoped. It records the episode’s interpretation that Akeso made Chinese innovation-drug capability harder for multinational pharma to dismiss, not an independent assessment of the company’s full pipeline or valuation.

156.生物医药的2026：当市场不再为BD躁动，中国药企的星辰大海才刚刚展开 revisits Akeso through Summit and makes Progression-Free vs Overall Survival the key interpretive problem. The episode keeps the PFS data important, but says OS had not yet reached the most optimistic market expectations, which turns Akeso into a test case for Biotech BD Data Validation Phase rather than only for China asset excitement.

Key Claims

• The episode says Akeso’s PD-1/VEGF bispecific produced strong Chinese phase-3 data, with PFS described by the guest as roughly doubling versus K药 in that context.
• The mechanism is treated as not fully explained: same-molecule dual targeting and tumor-local concentration are offered as possible reasons, not settled biology.
• Akeso anchors the source’s China Biotech Asset Repricing and Multinational Pharma Patent-Cliff Anxiety examples because Chinese data can force defensive global BD action.
• Episode 156 adds that Akeso also illustrates endpoint discipline: strong PFS should not be read as settled OS proof.

Connections

• PD-1/VEGF Bispecific - main technical asset frame.
• Merck / 默沙东 and Keytruda / K药 - global comparator and patent-cliff context in the episode.
• China Biotech Asset Repricing and Biotech License-Out Arbitrage - transaction and valuation context.
• Summit Therapeutics, Progression-Free vs Overall Survival, and Biotech BD Data Validation Phase - 2026 follow-up context.